Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mensa

Showing results (691-700 of 792) with videos related to

Pageof 80
Sort By:
Contemporary Clinical Trials Communications|January 26, 2021
Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocolX Solanich, A Antolí, N Padullés, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 21, 2021
First Description of Late-Onset Autoinflammatory Disease Due to Somatic NLRC4 MosaicismDaniela Ionescu, Alejandro Peñín-Franch, Anna Mensa-Vilaró, et al.
Hepatology (Baltimore, Md.)|January 28, 2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatmentFred Poordad, Franco Felizarta, Armen Asatryan, et al.
Hepatology (Baltimore, Md.)|September 20, 2017
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trialDavid Wyles, Fred Poordad, Stanley Wang, et al.
Infection|July 29, 2023
Multiplex real-time PCR FilmArray performance in the diagnosis of meningoencephalitis: lights and shadowsNéstor López, Genoveva Cuesta, Sara Rodríguez-Vega, et al.
The New England Journal of Medicine|August 16, 2013
Faldaprevir and deleobuvir for HCV genotype 1 infectionStefan Zeuzem, Vincent Soriano, Tarik Asselah, et al.
The Journal of Antimicrobial Chemotherapy|April 13, 2023
Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antiviralsTommaso-Francesco Aiello, Pedro Puerta-Alcalde, Mariana Chumbita, et al.
Infectious Diseases and Therapy|November 26, 2025
Growth in Anaerobic Bottles is an Independent Predictor of Mortality in Pseudomonas aeruginosa Bloodstream InfectionsDaniel N Marco, Laura Morata, Cristina Pitart, et al.
Plos One|December 10, 2015
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV InfectionTarik Asselah, Stefan Zeuzem, Vicente Soriano, et al.
The Lancet. Infectious Diseases|August 19, 2017
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trialXavier Forns, Samuel S Lee, Joaquin Valdes, et al.
Pageof 80

Showing results (691-700 of 792) with videos related to

Sort By:
Pageof 80
Contemporary Clinical Trials Communications|January 26, 2021
Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocolX Solanich, A Antolí, N Padullés, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 21, 2021
First Description of Late-Onset Autoinflammatory Disease Due to Somatic NLRC4 MosaicismDaniela Ionescu, Alejandro Peñín-Franch, Anna Mensa-Vilaró, et al.
Hepatology (Baltimore, Md.)|January 28, 2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatmentFred Poordad, Franco Felizarta, Armen Asatryan, et al.
Hepatology (Baltimore, Md.)|September 20, 2017
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trialDavid Wyles, Fred Poordad, Stanley Wang, et al.
Infection|July 29, 2023
Multiplex real-time PCR FilmArray performance in the diagnosis of meningoencephalitis: lights and shadowsNéstor López, Genoveva Cuesta, Sara Rodríguez-Vega, et al.
The New England Journal of Medicine|August 16, 2013
Faldaprevir and deleobuvir for HCV genotype 1 infectionStefan Zeuzem, Vincent Soriano, Tarik Asselah, et al.
The Journal of Antimicrobial Chemotherapy|April 13, 2023
Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antiviralsTommaso-Francesco Aiello, Pedro Puerta-Alcalde, Mariana Chumbita, et al.
Infectious Diseases and Therapy|November 26, 2025
Growth in Anaerobic Bottles is an Independent Predictor of Mortality in Pseudomonas aeruginosa Bloodstream InfectionsDaniel N Marco, Laura Morata, Cristina Pitart, et al.
Plos One|December 10, 2015
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV InfectionTarik Asselah, Stefan Zeuzem, Vicente Soriano, et al.
The Lancet. Infectious Diseases|August 19, 2017
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trialXavier Forns, Samuel S Lee, Joaquin Valdes, et al.
Pageof 80